Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 11OTHER 6NETWORK 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 34Leukemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Hematologic Neoplasms 4Recurrence 3Neoplasms 2Thrombocytopenia 1Sarcoma, Myeloid 1Sarcoma, Kaposi 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Myeloid 1Immunoproliferative Disorders 1HIV Infections 1Disease 1Congenital Abnormalities 1Acquired Immunodeficiency Syndrome 1

Interventions

Cytarabine 2Cyclosporine 2Cyclophosphamide 2midostaurin 1fludarabine phosphate 1Whole-Body Irradiation 1Transplantation 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Miransertib 1Methotrexate 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Daunorubicin 1Cord Blood Stem Cell Transplantation 1Clofarabine 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Congenital Abnormalities × Daunorubicin × Clear all
NCT00093600 2020-12-19

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Novartis

Phase 1 Completed
69 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡